FDA has approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis. Hepcludex is the first FDA-approved treatment for chronic HDV infection, a serious and life-threatening condition that can cause rapid development of liver fibrosis, liver cancer, liver failure, and even death.
FDA has issued warning letters to eight retailers for selling unauthorized tobacco products, including nicotine pouches and dissolvable tobacco products.
